Key Record Dates
| ClinicalTrials.gov Identifier: | NCT02485691 |
|---|---|
| Brief Title: | Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD) |
| First Submitted : | June 26, 2015 |
| First Submitted that Met QC Criteria : | June 26, 2015 |
| First Posted : | June 30, 2015 (Estimate) |
| Results First Submitted : | November 12, 2021 |
| Results First Submitted that Met QC Criteria : | February 11, 2022 |
| Results First Posted : | February 14, 2022 |
| Last Update Submitted that Met QC Criteria : | May 3, 2022 |
| Last Update Posted : | May 27, 2022 |